Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

This summary is generated by an algorithm. If you find any mistakes, let us know.

ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
UN

Unicorn Nest news

ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.

Source
Garuda Therapeutics Raises $72M in Series A Financing
Garuda Therapeutics Raises $72M in Series A Financing
UN

Unicorn Nest news

Garuda Therapeutics Raises $72M in Series A Financing

– Garuda Therapeutics from Cambridge develops off-the-shelf, durable blood stem cell therapies.
– Series A funding of $72m brings company valuation to more than $1b.
– The round was led by Aisling Capital, Northpond Ventures and Orbimed, supported by Cormorant Asset Management, Ridgeback Capital Investments, Monashee Investment Management, Sectoral Asset Management, National Resilience, Inc. (Resilience), Mass General Brigham Ventures, among others.

Source
858 Therapeutics Launches with Proven Team and $60 Million Series A Financing
858 Therapeutics Launches with Proven Team and $60 Million Series A Financing
UN

Unicorn Nest news

858 Therapeutics Launches with Proven Team and $60 Million Series A Financing

– 858 Therapeutics has raised $60m in Series A financing.
– The round was led by founding investor Versant Ventures, with participation from NEA, Cormorant Asset Management and Logos Capital.
– 858 is a biotechnology company developing novel therapeutics for the treatment of cancer.
– The company’s lead program is a novel small molecule inhibitor of the PI3K/mTOR pathway that is being developed for the treatment of solid tumors that are resistant to existing therapies.
– The Series A proceeds will allow 858 to enter the clinic with its lead candidates that have potential to treat cancers that are resistant to current therapies.

Source
Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases
Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases
UN

Unicorn Nest news

Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases

– Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, announced the completion of a $90m Series B financing to further advance Vigil’s proprietary pipeline of microglia-targeted medicines for the treatment of neurodegeneration.
– The financing was led by Vida Ventures with participation from existing investors Atlas Venture, Northpond Ventures and Hatteras Venture Partners as well as new investors including Surveyor Capital (a Citadel company), Cormorant Asset Management, Invus, OrbiMed, Rock Springs Capital, Deep Track Capital, Logos Capital, Pivotal bioVenture Partners, and Lightstone Ventures.

Source
Prime Medicine Raises $315M in Funding
Prime Medicine Raises $315M in Funding
UN

Unicorn Nest news

Prime Medicine Raises $315M in Funding

– Prime Medicine is a Cambridge MA-based biotechnology company developing gene editing technology.
– The company raised $115M in Series A funding and $200M in Series B funding.
– The Series A round was led by ARCH Venture Partners with participation from F-Prime Capital, GV, and Newpath Partners.
– The Series B included all Series A investors, plus Casdin Capital with participation from Cormorant Asset Management, Moore Strategic Ventures, Public Sector Pension Investment Board, Redmile Group and Samsara BioCapital.

Source
Tioga Medical, A Shifamed Portfolio Company, Closes $30M In Series B Financing
Tioga Medical, A Shifamed Portfolio Company, Closes $30M In Series B Financing
UN

Unicorn Nest news

Tioga Medical, A Shifamed Portfolio Company, Closes $30M In Series B Financing

– Tioga Medical, Inc. announced the initial closing of its committed $30M Series B financing.
– Led by The Capital Partnership (TCP), with participation from Cormorant Asset Management, AMED Ventures and Shifamed angel investors.
– The financing will be used to advance product development, support pre-clinical testing, and initiate clinical experience for the company’s novel transcatheter valve replacement technology.

Source
Umoja Biopharma Raises $210M in Series B Funding
Umoja Biopharma Raises $210M in Series B Funding
UN

Unicorn Nest news

Umoja Biopharma Raises $210M in Series B Funding

– Umoja Biopharma is a Seattle, WA-based oncology company.
– The company closed a $210m Series B financing.
– The round was co-led by SoftBank Vision Fund 2 and Cormorant Asset Management with participation from new investors, including RTW Investments, LP; Temasek; Presight Capital (the international venture arm of Christian Angermayer’s Apeiron Investment Group); Caas Capital; and an investment fund associated with SVB Leerink.

Source
Immunotherapy startup Umoja lands $210M, less than a year after raising $53M
Immunotherapy startup Umoja lands $210M, less than a year after raising $53M
UN

Unicorn Nest news

Immunotherapy startup Umoja lands $210M, less than a year after raising $53M

– Umoja Biopharma, a Seattle-based immunotherapy company, raised $210m in Series B funding.
– The round was led by SoftBank Vision Fund 2 and Cormorant Asset Management.
– New investors included RTW Investments, LP, Temasek, Presight Capital, Caas Capital and SVB Leerink.
– Funds also came from existing investors: MPM Capital, DCVC Bio, Qiming Venture Partners USA, Casdin Capital, The Emerson Collective and Alexandria Venture Investments.

Source
RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer
RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer
UN

Unicorn Nest news

RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer

– RayzeBio, Inc. announced a $108m Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X.
– Also participating were all of Rayze’s existing investors: venBio Partners, Versant Ventures, Samsara BioCapital, Redmile Group, Viking Global Investors, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, Logos Capital, Alexandria Venture Investments, and others.
– The targeted radiopharmaceuticals field represents a highly clinically validated modality that, until recently, has been underappreciated.
– With over $258m of capital raised since the company first debuted in the second half of 2020, RayzeBio has rapidly expanded its team, infrastructure, capabilities, and pipeline.

Source
Myra Vision Raises $17M In Series A Financings
Myra Vision Raises $17M In Series A Financings
UN

Unicorn Nest news

Myra Vision Raises $17M In Series A Financings

– Myra Vision, a maker of a glaucoma treatment device and Shifamed portfolio company, closed its $17M Series A financing.
– The round was led by The Capital Partnership (TCP) with participation from Cormorant Asset Management and Shifamed angel investors.
– The new investment will be used to advance product development, scale infrastructure, and expand the team in order to support the development of its glaucoma treatment device.

Source
NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets
NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets
UN

Unicorn Nest news

NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets

– NiKang Therapeutics Inc. announced the completion of an oversubscribed $200m series C financing led by Cormorant Asset Management, HBM Healthcare Investments and Octagon Capital Advisors with participations from a premier syndicate of funds including new investors EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Group, Pavilion Capital, funds and accounts managed by BlackRock, RA Capital Management, Surveyor Capital (a Citadel company), Samsara BioCapital, PFM Health Sciences, Invus, Janus Henderson Investors and Logos Capital.
– All existing investors including CBC Group, RTW Investments, LP, Lilly Asia Ventures, Matrix Partners China, and Casdin Capital participated in the financing.

Source
Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing
Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing
UN

Unicorn Nest news

Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing

– Numab Therapeutics AG, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, announced the closing of a CHF 100 million (approximately USD 110 million) Series C financing.
– The financing was co-led by new investors Novo Holdings and HBM Partners, with participation from additional new investors Forbion via its Forbion Growth Opportunities Fund, Cormorant Asset Management, BVF Partners L.P., RTW Investments L.P., funds and accounts under the management of BlackRock, Octagon Capital Advisors, and existing investors.

Source
Interius BioTherapeutics Raises $76M in Series A Financing
Interius BioTherapeutics Raises $76M in Series A Financing
UN

Unicorn Nest news

Interius BioTherapeutics Raises $76M in Series A Financing

– Interius BioTherapeutics, a Philadelphia, PA-based preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, raised $76m in Series A financing.
– The round was co-led by Cormorant Asset Management and Fairmount Funds, and joined by Bain Capital Life Sciences, Pfizer Ventures, RA Capital Management, Longwood Fund, Logos Capital, Osage University Partners and Quan Capital.

Source
GH Research Closes $125M Series B Financing
GH Research Closes $125M Series B Financing
UN

Unicorn Nest news

GH Research Closes $125M Series B Financing

– GH Research Ireland Ltd is a Dublin, Ireland-based clinical-stage biopharmaceutical company.
– The company closed a $125m Series B funding.
– The round was co-led by RA Capital and RTW Investments, LP, with participation from existing investor BVF Partners, and new backers Acuta Capital Partners, Boxer Capital, Cormorant Asset Management, Deerfield Management Company, Logos Capital, Surveyor Capital (a Citadel company), Venrock Healthcare Capital Partners and Verition Fund Management.

Source
Icosavax Closes $100 Million Series B Financing to Advance Bivalent RSV/hMPV Vaccine Candidate Into Clinical Trials
Icosavax Closes $100 Million Series B Financing to Advance Bivalent RSV/hMPV Vaccine Candidate Into Clinical Trials
UN

Unicorn Nest news

Icosavax Closes $100 Million Series B Financing to Advance Bivalent RSV/hMPV Vaccine Candidate Into Clinical Trials

– Icosavax closed a $100m Series B Financing, led by RA Capital Management and joined by Janus Henderson Investors, Perceptive Advisors, Viking Global Investors, Cormorant Asset Management, Omega Funds, and Surveyor Capital (a Citadel company).
– A previously announced funding from Open Philanthropy was included in this round.
– The proceeds of the financing will support the development of Icosavax’s bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccine program through initial clinical studies, continued evaluation of its SARS-CoV-2 vaccine candidate, and further expansion of the company’s pipeline of VLP vaccine candidates focused on protecting older adults from life-threatening respiratory diseases.

Pyxis Oncology Raises $152M Series B Round
Pyxis Oncology Raises $152M Series B Round
UN

Unicorn Nest news

Pyxis Oncology Raises $152M Series B Round

– Pyxis Oncology from Longwood Fund has closed a $152m Series B financing.
– The round was led by Arix Bioscience and co-led by RTW Investments, LP.
– New investors included Perceptive Advisors, RA Capital Management, Pfizer Ventures, BVF Partners, L.P., Janus Henderson Investors, Cormorant Asset Management, HBM Healthcare Investments, funds managed by Tekla Capital Management LLC, Acuta Capital Partners, Ridgeback Capital Investments, Surveyor Capital (a Citadel company), Laurion Capital Management, Logos Capital and LifeSci Venture Partners.

Source
EpimAb Biotherapeutics Raises $120M in Series C Financing to Advance Bispecific Programs and Broaden Clinical Pipeline
EpimAb Biotherapeutics Raises $120M in Series C Financing to Advance Bispecific Programs and Broaden Clinical Pipeline
UN

Unicorn Nest news

EpimAb Biotherapeutics Raises $120M in Series C Financing to Advance Bispecific Programs and Broaden Clinical Pipeline

– EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibody development, announced today the closing of a $120m Series C financing round.
– The round was co-led by China Merchants Bank International (CMBI) and Mirae Asset Financial Group (Mirae), and joined by Hony Capital, Cormorant Asset Management, Yanchuang Capital, Octagon Capital, renowned cultural entrepreneur and investor Adrian Cheng and ShangBay Capital, with strong participation from existing investors such as Decheng Capital, SDIC Fund, Sherpa Healthcare Partners, and Hidragon Capital.
– Proceeds from the financing will be used to fund the ongoing clinical development of EMB-01, EMB-02 and EMB-06, and to expand the company’s pipeline of novel bispecific antibodies and other biologics.

Source
Graphite Bio Secures $150 Million Series B Financing to Advance Pipeline of Next-Generation Gene Editing Therapies
Graphite Bio Secures $150 Million Series B Financing to Advance Pipeline of Next-Generation Gene Editing Therapies
UN

Unicorn Nest news

Graphite Bio Secures $150 Million Series B Financing to Advance Pipeline of Next-Generation Gene Editing Therapies

– Graphite Bio, a next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the close of an oversubscribed $150 million Series B financing.
– The company will use the funds to expand and advance into the clinic its pipeline of investigational high efficiency, targeted gene integration therapies with curative potential for serious diseases.
RA Capital Management and Rock Springs Capital led the financing with significant participation from new investors Cormorant Asset Management, Deerfield Management Company, Federated Hermes Kaufmann Funds, Fidelity Management & Research Company, Janus Henderson Investors, Logos Capital, OrbiMed, Perceptive Advisors, Surveyor Capital (a Citadel company), and Venrock Healthcare Capital Partners, joining existing investor Samsara BioCapital and founding investor Versant Ventures.

Source
Neurelis Raises $114M in Series D Financing
Neurelis Raises $114M in Series D Financing
UN

Unicorn Nest news

Neurelis Raises $114M in Series D Financing

– Neurelis, Inc. from San Diego develops novel therapies for epilepsy and other neurological disorders.
– The company closed $114m Series D financing round.
Cormorant Asset Management and Decheng Capital joined existing investors LYZZ Capital and HBM Healthcare Investments.
– In conjunction with this financing, Alexander Kwit has been appointed to the company’s Board of Directors.
– Kwit is a private investor who previously held the position of Executive Vice President of Royalty Pharma, a publicly traded company that buys royalty interests in biopharmaceutical products.

Source
AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators
AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators
UN

Unicorn Nest news

AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators

– AgomAb Therapeutics N.V. announced today the closing of a $74m Series B financing round led by Redmile Group, with participation from Cormorant Asset Management.
– All previous investors also participated in the round, including Advent France Biotechnology, Andera Partners, Boehringer Ingelheim Venture Fund, Omnes Capital, Pontifax, and V-Bio Ventures.
– The proceeds of the Series B will be used to fund clinical proof of concept of the lead program AGMB-101, an HGF-mimetic agonistic antibody, which is currently progressing through IND-enabling studies.
– The capital will also support further growth of the company’s pipeline of drug candidates designed to modulate regenerative pathways to induce functional organ recovery in acute and chronic diseases.

Source
Ventyx Biosciences Raises $114M in Funding
Ventyx Biosciences Raises $114M in Funding
UN

Unicorn Nest news

Ventyx Biosciences Raises $114M in Funding

– Ventyx is an Encinitas, California-based clinical-stage biotechnology company advancing a broad pipeline of potent and selective small-molecule drug candidates to treat inflammatory diseases and autoimmune disorders.
– The company raised $114m in Series C funding.
– The round was led by venBio Partners alongside new investors, including Third Point, RTW Investments, LP, Janus Henderson Investors, Wellington Management, OrbiMed, Surveyor Capital (a Citadel company), Farallon Capital, Vivo Capital, Logos Capital, Qiming Venture Partners USA, Cormorant Asset Management, and participation from founding investor New Science Ventures.

Source
DTx Pharma Closes $100M Series B Financing
DTx Pharma Closes $100M Series B Financing
UN

Unicorn Nest news

DTx Pharma Closes $100M Series B Financing

– DTx Pharma, Inc. from San Diego raised $100m in Series B financing.
– The round was led by RA Capital Management with participation from new investors Access Biotechnology, Surveyor Capital (a Citadel company), Cormorant Asset Management, Janus Henderson Investors, and Logos Capital and existing investors Friedman Bioventure Fund, Eli Lilly and Company, Viva BioInnovator (Viva Biotech Holdings, 1873.HK), and ExSight Ventures.
– The company intends to use the funds to utilize its FALCON fatty acid motifs to advance assets into clinical development across several therapeutic areas over the next few years.

Source
OnKure, Inc. Raises $55 Million Series B Financing
OnKure, Inc. Raises $55 Million Series B Financing
UN

Unicorn Nest news

OnKure, Inc. Raises $55 Million Series B Financing

– OnKure, Inc. raised $55m in a Series B financing.
– Proceeds will be used to advance the Company’s next generation histone deacetylase (HDAC) inhibitors further into clinical development and fund a growing pipeline of earlier stage molecules.
– The financing was led by Acorn Bioventures with participation from additional new investors Cormorant Asset Management, Surveyor Capital (a Citadel company), Samsara BioCapital, Perceptive Advisors and funds and accounts managed by BlackRock.
– In connection with the financing, Isaac Manke, Ph.D., Partner at Acorn Bioventures, and Andrew Phillips, Ph.D., Managing Director at Cormorant Asset Management, will join the OnKure board of directors.

Source
BlossomHill Therapeutics Inks $71M Series A
BlossomHill Therapeutics Inks $71M Series A
UN

Unicorn Nest news

BlossomHill Therapeutics Inks $71M Series A

– BlossomHill Therapeutics, a biopharmaceutical company focusing on oncology and autoimmune disorders, has raised $71m in a Series A financing round.
Cormorant Asset Management LLC led this round and is joined by Hercules BioVentures Partners LLC, OrbiMed Advisors, and Vivo Capital as co-leads.
– In conjunction with the financing, Bihua Chen of Cormorant Asset Management, George J. Lee, Ph.D., of Hercules BioVentures Partners, and Carl L Gordon, Ph.D., CFA, of OrbiMed Advisors joined the company’s Board of Directors.

Source
FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform
FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform
UN

Unicorn Nest news

FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform

– FogPharma announced the completion of a $107m Series C financing round.
– The round was led by venBio Partners with participation from new investors Cormorant Asset Management, Farallon Capital Management, Invus, funds and accounts advised by T. Rowe Price Associates, Inc.; HBM Healthcare Investments, Casdin Capital, and PagsGroup.
– Existing investors, including GV, 6 Dimensions Capital, Deerfield Management and Blue Pool Capital also participated in the oversubscribed round.
– FogPharma’s proprietary hyperstabilized α-helical peptides (Helicon™ peptides) are a new class of therapeutics that combine the targeting strength and specificity of antibodies with the broad tissue distribution, intracellular target engagement and oral dosing optionality of small molecules.

Source
1 2 3 58 59 60
Crunchbase icon

Content report

The following text will be sent to our editors: